How will HPV vaccines affect cervical cancer?

被引:211
作者
Roden, Richard [1 ]
Wu, T. -C.
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA
[3] Johns Hopkins Univ, Dept Obstet & Gynecol, Baltimore, MD 21231 USA
[4] Johns Hopkins Univ, Dept Mol Microbiol & Immunol, Baltimore, MD 21231 USA
关键词
D O I
10.1038/nrc1973
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer of the uterine cervix is the second largest cause of cancer deaths in women, and its toll is greatest in populations that lack screening programmes to detect precursor lesions. Persistent infection with `high risk' genotypes of human papillomavirus (HPV) is necessary, although not sufficient, to cause cervical carcinoma. Therefore, HPV vaccination provides an opportunity to profoundly affect cervical cancer incidence worldwide. A recently licensed HPV subunit vaccine protects women from a high proportion of precursor lesions of cervical carcinoma and most genital warts. Here we examine the ramifications and remaining questions that surround preventive HPV vaccines.
引用
收藏
页码:753 / 763
页数:11
相关论文
共 121 条
[81]   Spinning molecular immunology into successful immunotherapy [J].
Pardoll, DM .
NATURE REVIEWS IMMUNOLOGY, 2002, 2 (04) :227-238
[82]   The global health burden of infection -associated cancers in the year 2002 [J].
Parkin, Donald Maxwell .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (12) :3030-3044
[83]   NHPV16VLP vaccine induces human antibodies that neutralize divergent variants of HPV16 [J].
Pastrana, DV ;
Vass, WC ;
Lowy, DR ;
Schiller, JT .
VIROLOGY, 2001, 279 (01) :361-369
[84]   Cutting edge: Priming of CTL by transcutaneous peptide immunization with imiquimod [J].
Rechtsteiner, G ;
Warger, T ;
Osterloh, P ;
Schild, H ;
Radsak, MP .
JOURNAL OF IMMUNOLOGY, 2005, 174 (05) :2476-2480
[85]   Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease [J].
Reuter, JD ;
Vivas-Gonzalez, BE ;
Gomez, D ;
Wilson, JH ;
Brandsma, JL ;
Greenstone, HL ;
Rose, JK ;
Roberts, A .
JOURNAL OF VIROLOGY, 2002, 76 (17) :8900-8909
[86]   PERSPECTIVE - HYPOTHESIS - SERUM IGG ANTIBODY IS SUFFICIENT TO CONFER PROTECTION AGAINST INFECTIOUS-DISEASES BY INACTIVATING THE INOCULUM [J].
ROBBINS, JB ;
SCHNEERSON, R ;
SZU, SC .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (06) :1387-1398
[87]   Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes [J].
Roden, RBS ;
Yutzy, WH ;
Fallon, R ;
Inglis, S ;
Lowy, DR ;
Schiller, JT .
VIROLOGY, 2000, 270 (02) :254-257
[88]   INTERACTION OF PAPILLOMAVIRUSES WITH THE CELL-SURFACE [J].
RODEN, RBS ;
KIRNBAUER, R ;
JENSON, AB ;
LOWY, DR ;
SCHILLER, JT .
JOURNAL OF VIROLOGY, 1994, 68 (11) :7260-7266
[89]   Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope [J].
Roden, RBS ;
Armstrong, A ;
Haderer, P ;
Christensen, ND ;
Hubbert, NL ;
Lowy, DR ;
Schiller, JT ;
Kirnbauer, R .
JOURNAL OF VIROLOGY, 1997, 71 (08) :6247-6252
[90]   NEUTRALIZATION OF BOVINE PAPILLOMAVIRUS BY ANTIBODIES TO L1 AND L2 CAPSID PROTEINS [J].
RODEN, RBS ;
WEISSINGER, EM ;
HENDERSON, DW ;
BOOY, F ;
KIRNBAUER, R ;
MUSHINSKI, JF ;
LOWY, DR ;
SCHILLER, JT .
JOURNAL OF VIROLOGY, 1994, 68 (11) :7570-7574